Pharmacological inhibition of c-Kit in ALS murine models with masitinib results in significant amelioration of paralysis progression and a sharp decrease in MC infiltration into the degenerating peripheral motor pathways and NMJs [47–50]. The gene discussed is KIT; the disease is amyotrophic lateral sclerosis.